NMOSD News Briefs

Potential Biomarkers Identified for NMOSD Disease Activity and Treatment

Patients with neuromyelitis optica spectrum disorder (NMOSD) have significantly higher levels of plasma neurofilament light chain (pNfL) and plasma glial fibrillary acidic protein (pGFAP) compared to healthy controls, as found by researchers in China. These 2 proteins could serve as biomarkers for disease activity and treatment effects. “The dynamics of pNfL and pGFAP may help…

NMOSD Relapses Can Result in Disease Progression, Pain

A team of researchers discovered that aquaporin-4 immunoglobulin G-positive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) relapses can result in disease progression and pain, according to a study published in the Journal of Neuroimmunology. “Without effective treatment, nearly all (80%–90%) patients with [NMOSD] experience recurrent episodes of optic neuritis (ON), transverse myelitis (TM), or a mixed…

Association Found Between Disability and Quality of Life in Patients With NMOSD

Neuromyelitis optica spectrum disorder (NMOSD)-related disability was associated with quality of life (QoL) measures in patients with NMOSD, according to a study published in Multiple Sclerosis and Related Disorders. “Disability accrual is a direct result of relapses in NMOSD; therefore, early intervention for relapse prevention is key to improving long-term QoL outcomes,” the authors of…

Inebilizumab-cdon Receives Positive Opinion From European Union Committee for NMOSD

Inebilizumab-cdon (Uplizna®) received a positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of neuromyelitis optica spectrum disorder (NMOSD), according to a press release from Horizon Therapeutics plc. The decision is based on the results of a phase 2/3 clinical trial called N-MOmentum, which compared…

AZD1222 COVID-19 Vaccine Potentially Associated With MS and NMOSD Relapse

Researchers from Brazil reported cases of relapse of multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) after vaccination with the first dose of the AZD1222 COVID-19 vaccine. The findings were recently published in the journal Multiple Sclerosis and Related Disorders. Their observations suggest that these relapses might be a rare adverse event of the…

How the COVID-19 Pandemic Changed Attitudes in NMOSD Patients

Anxiety about the COVID-19 pandemic has decreased over time in patients with neuromyelitis optica spectrum disorder (NMOSD), according to a new study published in the Journal of the Neurological Sciences. The study found that 80% of NMOSD patients (n=96) experienced anxiety during the first 3 months of the pandemic. Patients were surveyed again 9 months…

Potential New Biomarker Could Predict NMOSD Prognosis

A high neutrophil-to-lymphocyte ratio may be associated with a high relapse rate and poor recovery in neuromyelitis optica spectrum disorder (NMOSD), a new study published in BMC Neurology found. According to the researchers, the neutrophil-to-lymphocyte ratio could therefore be used as a prognostic indicator for the disease. The pathogenesis of NMOSD is not fully understood,…

Durhane Wong-Rieger

Dr. Durhane Wong-Rieger on the Challenges Faced by Rare Disease Patients in Canada

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Durhane Wong-Rieger, PhD, president and CEO of the Canadian Organization for Rare Disorders (CORD) and chair of Rare Diseases International (RDI). Dr. Wong-Rieger talks about the challenges of diagnosing and treating diseases in Canada, as well as advancing access to therapies around the globe. Read the…

Next post in Podcasts